Addressing the complexity of central nervous system diseases by setting up Multidimensional Combination Drugs (MCD).

About us

We founded Helios Neopharma with the vision of making a radical shift in the way drugs are designed and developed to address the deadlock of current therapeutic strategies to cure central nervous system diseases.

Helios™ technology platform

At Helios Neopharma we are able to grow mini-brains in the lab directly from patient cells while maintaining disease signatures such as the aging state and epigenetic alterations. Our technology will break new ground for fundamental science and drug discovery to cure Alzheimer’s or Parkinson’s.

With its sophisticated organoids brain model and deep AI-driven analysis, Helios Neopharma will provide the most advanced service to reveal complex disease signatures and discover new drugs

helios tech image

Drug discovery

Central nervous system disorders are complex and caused by interactions between many pathological processes, each process being orchestrated by a network of genes creating a pathological network. Many drug discoveries fail because researchers target only “one process-one gene” at a time.

MCDs are safe synergistic multi-compound networks that tackle in a concerted manner strategic nodesto restore physiological network of central nervous system.

We harness the full potential of data and advanced artificial intelligence/machine learning tools to predict safe MCDs with a higher probability of clinical success.

The team

Contact

Faculté de Médecine - Site Cochin, 24 Rue du Faubourg Saint-Jacques, 75014 Paris

Our Partners